Sudarshan Pharma schedules 18th AGM for September 22, 2026

1 min read | Published on 29 Aug 2026, 02:45 PM |Updated on 01 Sept 2026, 11:19 AM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Sudarshan Pharma schedules 18th AGM for September 22, 2026
Agenda includes adoption of FY26 financial statements
Dr. Anil Ghogare seeks re-appointment as director
E-voting opens on September 19 and closes on September 21

*this image is generated using AI for illustrative purposes only.

Sudarshan Pharma Industries has scheduled its 18th Annual General Meeting for Tuesday, September 22, 2026. The meeting will be conducted through video conferencing or other audio-visual means at 3:00 pm IST.

The primary agenda includes the adoption of audited financial statements for the fiscal year ended March 31, 2026. Shareholders will also vote on the re-appointment of Dr. Anil Ghogare as a director.

Director Re-Appointment

Dr. Anil Ghogare retires by rotation and offers himself for re-appointment as a Non-Executive Non-Independent Director. He was originally appointed to the board on November 10, 2023.

Detail	Information
Designation	Non-Executive Non-Independent Director
Age	65 years
Education	MBA (Finance), PhD (Pharmaceutical Chemistry), M.Tech (Chemical & Instrumentation)
Experience	37 years in Fermentation Technology
Remuneration Last Drawn	Nil
Shareholding	Nil

Dr. Ghogare holds a PhD in Pharmaceutical Chemistry from Mumbai University and an M.Tech from the Indian Institute of Technology, New Delhi. He possesses 37 years of experience in fermentation technology and serves as a regulatory consultant for pharmaceutical plant design and technology transfers.

Meeting Logistics

The company will provide remote e-voting facilities through National Securities Depository Limited. The voting period begins on Saturday, September 19, 2026, at 9:00 am and ends on Monday, September 21, 2026, at 5:00 pm.

The record date for determining voting eligibility is Tuesday, September 15, 2026. Members can attend the meeting via video conferencing starting 15 minutes before the scheduled time. Proxy appointments are not available for this meeting.

Historical Stock Returns for Sudarshan Pharma Industries

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.25%	+1.29%	+12.36%	+70.72%	+34.68%	+476.37%

How might the re-appointment of Dr. Anil Ghogare influence Sudarshan Pharma's strategic focus on fermentation technology and regulatory compliance in upcoming quarters?

What specific financial performance metrics or growth targets are shareholders likely to scrutinize in the audited statements for FY2026?

Could the absence of proxy appointments for this AGM impact shareholder participation rates and voting outcomes compared to previous years?

Sudarshan Pharma Industries

View Company Insights

View All News

Sudarshan Pharma promoters pledge 1.33 crore shares to Satin Finserv

1 min read | Published on 26 Aug 2026, 08:32 PM |Updated on 26 Aug 2026, 08:32 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Hemal V Mehta and Sachin V Mehta each pledged 66.50 lakh shares
Encumbrance created in favor of Satin Finserv Limited on August 25, 2026
Reason cited as security for loans taken by third parties
Total encumbered holding for both promoters rises to 5.21%
Disclosures filed under SEBI SAST Regulations 31(1) and 31(2)

*this image is generated using AI for illustrative purposes only.

Sudarshan Pharma Industries promoters Hemal V Mehta and Sachin V Mehta pledged a combined 1.33 crore equity shares on August 25, 2026. The encumbrance was created in favor of Satin Finserv Limited as security for loans taken by third parties.

Pledge Details

Both promoters disclosed the creation of pledges under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosures were filed with BSE Limited on August 26, 2026.

Promoter	Shares Pledged	% of Capital	Pre-existing Encumbered Shares	Total Encumbered Post-Event
Hemal V Mehta	66,50,000	2.61%	66,00,000	1,32,50,000 (5.21%)
Sachin V Mehta	66,50,000	2.61%	66,00,000	1,32,50,000 (5.21%)

Hemal V Mehta holds 6,85,21,020 shares, representing 26.93% of the total share capital. Sachin V Mehta holds 7,07,05,470 shares, accounting for 27.79% of the total share capital.

What the Numbers Show

The new pledge increases the total encumbered stake for both promoters to 5.21% of the company’s total share capital. This indicates that roughly one-fifth of each promoter’s individual holding is now pledged, as Hemal V Mehta’s encumbered portion rises from 2.59% to 5.21%, and Sachin V Mehta’s follows the identical trajectory.

Historical Stock Returns for Sudarshan Pharma Industries